BioCentury
ARTICLE | Product Development

Past not prologue

How luck and good timing factored into Loxo’s back-to-back home runs at ASCO

June 9, 2018 1:43 AM UTC

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to make it a hat trick, given the third program is lined up more to meet a known need than break new ground.

Loxo’s first two programs came out of a 2013 partnership with Array BioPharma Inc., which yielded larotrectinib (LOXO-101) and LOXO-292, two compounds at the leading edge of a trend toward redefining cancers based on molecular profile rather than tissue of origin...